OncoSil Medical – Interview on CE Mark and Growth Plans
OncoSil Medical is pleased to provide details of an interview with Chief Executive Officer and Managing Director Daniel Kenny and Finance News Network to discuss the Company’s CE Mark progress and growth plans.
OncoSil Medical is focused on the commercialisation of its lead product candidate, the OncoSilTM localised radiation treatment for cancer. It is concurrently seeking a Conformité Européenne (CE) Mark for OncoSilTM for pancreatic and primary liver cancer (HCC), which would facilitate commercialisation in the European Union and other major markets (including Australia, Canada and Singapore), and US approval via the US FDA.
The Company was granted a Fast Track review for its CE Mark with the European regulator in October this year and expects to receive the outcome of its CE Mark application in the near future.
http://www.finnewsnetwork.com.au/MediaCenter/AsxMediaCenter.aspx?Site=FNN660
http://www.oncosil.com.au/oncosil-medical-interview-on-ce-mark-and-growth-plans/
http://www.finnewsnetwork.com.au/Presentations/CEO_Sessions_2015/Nov_Syd/OncoSil_Syd_1115.html
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
-0.070(5.69%) |
Mkt cap ! $16.49M | |||
| Open | High | Low | Value | Volume |
| $1.25 | $1.25 | $1.11 | $72.36K | 60.96K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9286 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.18 | 412 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |